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Abstract
Current cytogenetics has largely focused its efforts on the identification of recurrent karyotypic alterations, also
known as clonal chromosomal aberrations (CCAs). The rationale of doing so seems simple: recurrent genetic
changes are relevant for diseases or specific physiological conditions, while non clonal chromosome aberrations
(NCCAs) are insignificant genetic background or noise. However, in reality, the vast majority of chromosomal
alterations are NCCAs, and it is challenging to identify commonly shared CCAs in most solid tumors. Furthermore,
the karyotype, rather than genes, represents the system inheritance, or blueprint, and each NCCA represents an
altered genome system. These realizations underscore the importance of the re-evaluation of NCCAs in cytogenetic
analyses. In this concept article, we briefly review the definition of NCCAs, some historical misconceptions about
them, and why NCCAs are not insignificant “noise,” but rather a highly significant feature of the cellular population
for providing genome heterogeneity and complexity, representing one important form of fuzzy inheritance. The
frequencies of NCCAs also represent an index to measure both internally- and environmentally-induced genome
instability. Additionally, the NCCA/CCA cycle is associated with macro- and micro-cellular evolution. Lastly, elevated
NCCAs are observed in many disease/illness conditions. Considering all of these factors, we call for the immediate
action of studying and reporting NCCAs. Specifically, effort is needed to characterize and compare different types of
NCCAs, to define their baseline in various tissues, to develop methods to access mitotic cells, to re-examine/
interpret the NCCAs data, and to develop an NCCA database.
Keywords: Clonal Chromosome Aberrations or CCAs, Fuzzy inheritance, Genome instability, Genome theory,
Heterogeneity, Non Clonal Chromosome Aberrations or NCCAs, NCCA/CCA cycle, Parts inheritance, System
inheritance
Background
Large scale –omics have revealed the surprising observa-
tion that stochastic alterations at various genetic and
non-genetic levels are overwhelming [1]. These levels
range from gene mutation, copy number variation, tran-
scription regulation, protein degradation, molecular
pathway switching/genetic network rewiring, and karyo-
type changes, to disease progression and therapeutic re-
sponse [2]. Such a high “noise” level challenges the
rationale and strategy of searching solely for the recur-
rent molecular patterns in the name of understanding
bio-specificity-defined mechanisms. This approach has
unconsciously altered the key feature of the Biosystems
we are studying [1]. Interestingly, the seemingly random
“non clonal chromosome aberrations,” or NCCAs, have
long been observed in both normal and disease condi-
tions, and the importance of studying this stochasticity
or “noise” at the karyotype level has been vigorously
pushed by a few groups (Table 1). However, the overall
response to this effort has been rather limited due to the
current cytogenetic practice, in which the main effort is
the documentation of recurrent or “clonal chromosome
aberrations,” or CCAs. In this perspective, we will briefly
review NCCAs, an important but often ignored topic in
molecular cytogenetics. We will first compare the con-
cept of NCCAs and CCAs, challenge the general notion
of solely focusing on recurrent patterns that ignore the
majority of cases with NCCAs, and introduce new types
of NCCAs; we then will discuss the importance of using
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Table 1 Examples of NCCAs related studies
Ref. #
(I) General description and classification of NCCAs Wolman SR et al. (1984). Can Genet Cytogenet 16: 49-64 [22]
Casalone R et al. (1992). Hum Genet 90(1–2): 71-8 [86]
Mandahl N et al. (1994). Genes Chromosomes Cancer 9(3): 207-15 [87]
Atkin NB et al. (2003). Cytogenet Cell Genet 101(2): 99-102 [25]
Roschke AV et al. (2003). Cancer Res 63(24): 8634-47 [45]
Heng HH et al. (2006). J Cell Biochem 98: 1424-35 [17]
Heng HH et al. (2006). Genome 49: 195-204 [18]
Mitelman F (2006). NCI, NIH, USA [42]
Bayani J et al. (2007). Semin Cancer Biol 17(1): 5-18 [15]
(II) Variable forms of NCCAs have been reported
Various numerical/ structural aberrations Erenpreisa J et al. (2005). Cell Biol Int 29(12): 1005-11 [88]
Erenpreisa J et al. (2010). Oncogene 29(40): 5447-51 [89]
Chromosome fragmentations (C-Frag) Stevens JB et al. (2007). Cancer Res 67 (16): 7686-94 [90]
Sticky chromosomes Heng HH et al. (2013). Cytogenet Genome Res 139(3): 144-57 [66]
Chromosome bridge Gisselsson D (2001). Atlas Genet Cytogenet Oncol Haematol 5(3): 236-43 [91]
Defective mitotic figures (DMF) Heng H et al. (1988). Mutat Res 199(1): 199-205 [32]
Smith L et al. (2001). Proc Natl Acad Sci U S A 98(23): 13300-5 [92]
Genome/ karyotype/ chromosome chaos Heng HH (2006). J Cell Physiol 208: 461-72 [16]
Duesberg P (2007). Sci Am 296(5): 52-9 [39]
Heng HH (2007). FASEB: Nuclear Structure and Cancer [55]
Liu G et al. (2014). Cell Cycle 13(4): 528-37 [62]
Karyoplast budding Walen KH (2005). Cell Biol Int 29(12): 1057-65 [93]
Giant nuclei Walen KH (2010). Cell Biol Int 34(8): 867-72 [94]
Heng HH et al. (2013). Cytogenet Genome Res 139(3): 144-57 [66]
Liu G et al. (2014). Cell Cycle 13(4): 528-37 [62]
Zhang S et al. (2014). Oncogene 33(1): 116-28 [69]
(III) Mechanism of NCCAs Heng HH et al. (2006). J Cell Physiol 208: 461-72 [16]
Heng HH et al. (2011). Genomics 98(4): 242-52 [49]
Vincent MD (2011). Adv Cancer Res 112: 283-350 [95]
Stepanenko AA et al. (2012). Biopolymers and Cell 28(4):267-80 [96]
Huang S (2013). Cancer Metastasis Rev 32(3–4): 423-48 [97]
Duesberg P & McCormack (2013). Cell Cycle 12(5):783-802 [98]
Horne SD et al. (2014). Front Genet 134(9): 2074-87 [65]
Horne SD et al. (2015). eLS: 1-9 [12]
(IV) Significance of NCCAs; they are linked to:
Chromosomal instability (CIN) Barrios L et al. (1991). Hum Genet 88: 39-41 [28]
Gisselsson D et al. (2001). Proc Natl Acad Sci U S A 98(22): 12683–8. [99]
Ye C et al. (2007). Cytogenet Genome Res 18: 237-46 [11]
Foster N et al. (2009). Cytogenet Genome Res 127(1): 9-20 [38]
Ye C et al. (2009). J Cell Physiol 219: 288-300 [59]
Heng HH et al. (2013). Cytogenet Genome Res 139(3): 144-57 [66]
Jackson TR et al. (2013). Cell Cycle 12(3): 430-41 [70]
Gene defects Shen KC et al. (2005). Cancer Res 65: 8747-53 [9]
Heng HH et al. (2006). J Cell Phyisol 208: 461-72 [16]
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NCCAs to measure system instability. As the karyotype
represents a new type of genetic information, the system
inheritance, NCCAs are not “noise;” rather, they func-
tion as the basis of genome heterogeneity, which is the
essential form of genomic complexity and one of the
pre-conditions for many diseases. We will further apply
the cellular evolutionary mechanism to illustrate the dis-
ease process, and integrate the elevated NCCAs and
NCCA/CCA cycle as the key condition for cellular adap-
tation, as well as the price to pay for the trade-off. Fi-
nally, since the variable karyotype serves as a good
model to study fuzzy inheritance, the cytogenetics and
cytogenomics field has positioned itself to tackle the im-
portant issue of how genome alteration unifies other
types of molecular analyses, especially with the power of
monitoring large number of individual cells within a de-
fined cellular population. We thus call for the immediate
action of documenting and reporting the data on
NCCAs and their dynamic patterns in normal and dis-
ease conditions. This effort will have a profound impact
beyond the field of cytogenetics and cytogenomics, as
these stochastic alterations are also important for gene
mutation and epigene regulation studies.
NCCA or CCA? That is the question
The cytogenetic classification of karyotype aberrations has
traditionally played a key role in genetic analysis and its
applications in medical genetics. The establishment of
normal karyotypes and the identification of major recur-
rent chromosomal aberrations have contributed to our
understanding of the mechanism of many genetic diseases.
This, in turn, has framed our approach in developing new
prognostic and diagnostic methods. Additionally, studying
patterns of karyotypic evolution has been useful in im-
proving our grasp of organismal evolution [3–11]. To
date, the majority of this achievement has been based on
the analysis of CCAs; only in some specific cases, such as
radiation-induced chromosomal breakages and chromo-
somal changes from patients with chromosomal instability
syndromes, have the NCCAs involved been analyzed [12].
As for somatic polyploidy-diploid studies, many stochastic
transitions generate NCCAs, even though they are often
considered as tetraploid or near-diploid (Table 1). This
can also apply to the B chromosome, as well as small
supernumerary marker chromosomes [13, 14]. Prior to
discussing this further, let us first briefly review the defin-
ition and classification of NCCAs and CCAs.
Table 1 Examples of NCCAs related studies (Continued)
Sharpless NE et al. (2001). Mol Cell 8(6): 1187-96 [46]
Environmental stress Stevens JB et al. (2011). Cell Death Dis 2: e178
DOI: 10.1038/cddis.2011.60.
[100]
Disease conditions/ prediction, as well as normal
tissue/aging processes
Hsu TC (1983). Hereditas 98: 1-9 [33]
Biesterfeld S et al. (1994). J Clin Pathol 47(1): 38-42 [101]
Spitz MR et al. (1994). Cancer Detect Prev 18: 299-303 [102]
Hagmar L et al. (1998). Recent Results Cancer Res 154: 177-84 [31]
Bonassi S et al. (2000). Cancer Res 60: 1619-25 [29]
Karashima T et al. (2000). Cancer Genet Cytogenet 120(2): 148-54 [103]
López de Mesa R et al. (2000). Cancer Genet Cytogenet 121(1): 78–85. [104]
Kasahara K et al. (2002). Cancer Genet Cytogenet 137(1): 59-63 [105]
El-Zein R et al. (2005). Cancer Epidemiol Biomarkers Prev 14: 748-52 [30]
Kolusayin Ozar MO et al. (2005). J Exp Clin Cancer Res 24: 217-22 [34]
Petersen I et al. (2009). Lung Cancer 65(3): 312-8 [106]
Fenech M (2011). Mutagenesis 26(1): 63-7 [107]
Heng HH et al. (2016). Curr Genomics (submitted) [108]
Chemotherapy/radiation treatment (and they occur
in the development of resistance)
Scott D et al. (1999). Int J Radiat Biol 75: 1 [36]
Duesberg P et al. (2007). Drug Resist Updat 10(1–2): 51-8 [40]
Heng HH et al. (2010). Curr Drug Targets 11: 1304-16 [56]
Evolutionary potential (both in vitro and in vivo) Rancati G et al. (2008). Cell 135(5): 879-93 [109]
Heng HH et al. (2009). Bioessays 31(5): 512-25 [48]
Pearse AM et al. (2012). Cancer Genet 205(3): 101-12 [110]
Potopova TA et al. (2013). Cancer Metastasis Rev 32(3–4): 377-89 [111]
Stepanenko A et al. (2015). Mutat Res 771: 56-69 [58]
Heng et al. Molecular Cytogenetics  (2016) 9:15 Page 3 of 12
a. Definitions and classifications:
Current cytogenetics defines a clonal chromosome
aberration (CCA) as a given chromosome aberration
which can be detected at least twice within 20 to 40
randomly examined mitotic figures. Based on this
definition, the frequency of CCA needs to be higher
than 5-10 % in an examined cell population. In lit-
erature, however, when a CCA is reported, re-
searchers often refer to aberrations with frequencies
that are over 30 %. Using the cut-off line of CCAs, a
non-clonal chromosome aberration (NCCA) should
refer to aberrations observed at a frequency of less
than 5 %. According to our experience, we usually
examine 50–100 mitotic figures when scoring
NCCAs and CCAs, and therefore, 4 % is used as the
cut-off (i.e., less than 2 in 50 mitotic cells examined);
this is done even though, theoretically, the cut-off
line could be 1 % or lower (i.e., if more than 100 mi-
totic figures are used).
NCCAs can be classified into structural and
numerical types [11, 12, 15]. There are increased
structural types of NCCAs being reported (See
Table 1, and Fig 1). Within the punctuated
macro-cellular evolutionary phase, massive amounts
of NCCAs can be detected, often coupled with
complex chromosomal aberrations.
In addition to being classified by their structural and
numerical differences, CCAs can be further
classified into different types. In the “watching
karyotype evolution in action” experiments, there
are many short-lived transitional CCAs (i.e., those
CCAs detectable before the establishment of a cell
line), and late-stage, more stable CCAs (which serve
as the featured aberrations for the cell line or the
specific cancer sample). In the clinic, there are some
signature CCAs which can be used as a common
marker for a given disease, such as the Philadelphia
chromosome for chronic myelogenous leukemia or
CML, and an extra chromosome 21 for Down’s
syndrome. In general, CCAs dominate in the
stepwise microcellular phase of cancer evolution.
More information on NCCAs/CCAs can be found
in our previous publications [11, 16–18].
b. NCCAs have been considered as insignificant
genetic “noise”:
Starting from late 1960s, most cytogenetic methods
(i.e. various chromosomal banding, FISH, SKY/m-
FISH, and CGH) are designed to identify specific
chromosomal abnormalities (both in individual
chromosomes and particular regions of a given
chromosome). These major technological
achievements have pinpointed many genetic
aberrations of specific diseases, including the linking
of the Philadelphia chromosome (Ph) to CML [19],
as well as that of recurrent translocations to an
array of subtypes of blood cancer [20]. When
molecular cloning became dominant in the field of
human genetics, karyotyping became a powerful tool
for the process of gene cloning. It is no surprise that
more attention has been focused on the recurrent
abnormalities, as they should host key genes
important for diseases. In contrast, the large amount
of NCCAs detected from the majority of cases have
been considered as insignificant “noise” [21]. Most
cytogenetic reports do not include NCCA data. The
art of karyotype studies seems to be in the
identification of the recurrent patterns from the
background of NCCA noise. For example, in some
earlier cytogenetic reports, despite the fact that
NCCAs were commonly observed, and that they
were clearly more common in tumor-derived tissue
than in normal culture, it was concluded that a con-
siderable fraction of breast cancers are composed
predominantly of diploid cells [22]. These reports
have been considered by many as evidence to sup-
port the viewpoint that many cancers do not display
abnormal karyotypes. In addition to the limited iden-
tification power of G-banding and the bias of
methods that authors had mentioned, the ignorance
of NCCAs was a main reason for this. Newer refer-
ences have stated that, for the majority of solid tu-
mors, karyotype aberration is a common feature
[23–26]. Cancer genome sequencing projects have
also confirmed that chromosome level abnormality
is overwhelming in solid cancers [27], and that far
more structural alterations than gene mutation/copy
number variations are involved when comparing pri-
mary tumors to metastatic cancer.
c. NCCAs have been sporadically but persistently
studied by some investigators:
Nevertheless, limited research on NCCAs persists,
due to the fact that they are overwhelmingly
present (Table 1). This is especially true when
their frequencies are very high, and when the
karyotypes involve highly complex translocations.
For example, elevated NCCAs have been observed
from blood cultures of cancer patients,
particularly when subsequent to radiation or
chemotherapy. It is also well known that for
cancers featuring chromosomal instability, this
increased chromosomal instability is reflected by
elevated NCCAs [8, 9, 26–38]. Of course, most of the
aneuploidy in solid tumors is NCCA type [25, 39–41],
and most of the chromosomal aberrations detected
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during chemotherapy regimens are nonclonal and
unbalanced (>75 %). Interestingly, for all those
examined tumor cases reported so far, the majority of
them display different aberrations, which should
ultimately lead to the realization that NCCAs are
fundamentally important and common CCAs are only
detectable in a minority of cases [42, 43]! In fact, in
current databases, NCCAs are under-represented due
to publication bias. Most researchers will only write a
paper when the recurrent chromosomal aberrations
are identified, leaving most data of NCCAs
unreported.
The reason that the research community ignores
NCCAs is simple: the complex cases of NCCAs
do not fit with the prediction of the gene
mutation theory of genetic diseases. In the case of
cancer, following the successful cloning of the
bcr-abl gene from CML, many researchers
became and still are convinced that they must
find the recurrent pattern of most solid tumors,
not knowing the distinctive evolutionary dynamics
between CML and the majority of cancers [44].
In addition, based on the gene mutation theory of
cancer (wherein for each cancer type, there
should be only a few key driver gene mutations),
the large scale of stochastic genome alterations
does not make any sense [1, 44]. Equally
misleadingly, a CGH profile based on a mixed
cell population does indeed wash off many
NCCAs. As soon as some common recurrent
CCAs are identified (even at lower frequencies),
researchers no longer consider the large number
of co-existing NCCAs, as if considering the
NCCAs as “noise” can bring closure to a specific
investigation. Furthermore, people have reasoned
(or hoped) that if we have more precise
identification methods in the future, such as
multiple color SKY and high-resolution CGH, as
well as more high quality samples, then we
should be able to find the limited recurrent
Fig. 1 Examples of NCCAs: a DMF image (reversed DAPI image) detected from mouse cell culture. Left portion shows the de-condensed
chromosomes are tangling together, while some normal condensed chromosomes are nearby. b SKY image of a chaotic genome detected from a
Dox treated mouse cell. Each normal chromosome should have one unique color. However, for these massively re-organized chromosomes, there are
multiple colors detected from each single chromosome, indicating the multiple events of chromosomal shattering and stitching. Note that there are
many extremely long chromosomes. c An image of a giant nucleus (DAPI image) detected from HT-29 cells cultured in situ. Typical normal-sized
nuclei are surrounding the giant nucleus. d An image of a cluster of cells derived from one giant nucleus. Since many of these cells are stochastically
generated and display different amounts of DNA, these cells represent NCCAs when they enter into metaphase. Live imaging shows that there are
continuous division /fusion events for unstable cancer cells, suggesting a new means of generating fuzzy inheritance
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pattern. To date, current cytogenetic/cytogenomic
technologies have failed to identify the magic
pattern, and researchers continue to hope for
more powerful future methods. Based on the
overwhelming amount of NCCAs and the
diversity of CCAs detected, why not ask a simple
question: what if there are no simple and
common CCAs for the majority of cancers?
Clearly, there is a paradox regarding NCCAs and
CCAs in the literature. On one hand, elevated
NCCAs can be detected in both tumor samples
and an individual’s circulating lymphocytes; in the
latter case, this is often coupled with an increased
cancer risk following exposure to irradiation and
carcinogens (see Table 1). In fact, clinical samples
display highly dynamic karyotypic data [42, 43],
and even for such well-established cell lines as
those of the NCI-60 drug-screening panel,
NCCAs are common [45]. Additionally, increased
molecular studies have linked specific gene
mutations to stochastic chromosomal aberrations
[9, 16, 46, 47]. On the other hand, the majority
of researchers are not interested in this highly
significant avenue, despite the fact that they have
failed to identify key recurrent patterns for a vast
majority of cases. We realized that systematic
research about the NCCA and its dynamic rela-
tionship with CCAs within an evolutionary
context needed to be used to change the popular
yet incorrect attitude towards system
heterogeneity. Only when we have the correct
framework to appreciate NCCAs will people take
action. Prior to our series of studies, these seemly
random chromosomal changes failed to link
the common mechanisms. Since our NCCA
research has been ongoing for over a decade,
only some highlights will be mentioned here.
More information can be found from our
recent publication [1].
Following the trace of NCCA/CCA dynamics
through the use of various experimental systems
to watch somatic cell evolution in action, and
especially upon the detection of NCCAs from
normal individuals and elevated NCCAs from
various disease conditions, we realized the
importance of these types of aberrations. Even
though the frequency of stochastic translocations
is low for many cases, there are many different
types of NCCAs, and some of them have been
ignored for decades (Table 1) (Fig 1). Collectively,
the frequencies of NCCAs are high. It was thus
clear to us that we needed to promote new
research based on NCCA/CCA cycles and the
evolutionary dynamics between potential and end
products, rather than solely focusing on highly
limited CCAs. To achieve this goal, we need
demonstrate the biological significance of
stochastic genome alterations in the context of
genetic information and genome instability-
mediated somatic cell evolution.
NCCAs are not insignificant “noise” but rather a highly
significant feature of the genome system
a. Genome (not gene) defines genetic blueprint:
According to the genome theory, genetic
information can be divided into different main types:
the gene-defined “parts inheritance” (i.e., how gene
codes for specific protein) and the genome-defined
“system inheritance” or blueprint (i.e., how genome
codes the genetic network for a given species) [1].
Since the relationship of all gene interaction is de-
fined by the physical matrix among genes (the inter-
active potential under various environmental
conditions), the order of the genes along an individ-
ual chromosome and among different chromosomes
determines the genetic networks within 3-
dimensional nuclei [1, 48, 49]. Interestingly, the
maintenance of karyotype-mediated genetic informa-
tion is through sexual reproduction [50–52].
The gene and genome relationship mimics the
relationship between parts and the whole. Not only
there is no simple accumulative relationship between
gene and genome; quantitatively speaking, genome
level change often is much greater than individual
gene mutations, as the genome functions as a
package unit for evolutionary selection [1, 48]. All
altered genomes, like NCCAs, represent altered
systems.
b. NCCAs represent genome level heterogeneity and
can serve as an index for genome instability:
Knowing that the essential function of the karyotype is
to encode key genetic information (genetic blueprint),
it is easier to appreciate the importance of karyotype
variations, as these represent the altered system
inheritance. Our research has demonstrated that
NCCAs are not “noise” after all, as NCCAs-formed
genome heterogeneity is a key feature of the bio-
logical system that also functions as a layer of com-
plexity [1, 53, 54]. Using cancer evolution as an
example, almost all genetic and non-genetic factors
that can contribute to carcinogenesis can ultimately
(either directly or indirectly) be linked to elevated
NCCAs . During the punctuated phase of macro-
cellular evolution, NCCAs are dominant, coupled
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with a large number of transitional CCAs. Only
during the stepwise phase of micro-cellular evolu-
tion are CCAs persistent. Importantly, different
runs of evolution often lead to different CCAs, as
many CCAs can serve as the end product of evolu-
tion. In other words, most cancers will display dif-
ferent karyotypes or combinations of NCCAs and
variable CCAs. Since heterogeneity is the essential
condition for the evolutionary process itself, re-
searchers who seriously study cancer should not
consider NCCAs as noise. Many conclusions from
linear model systems that significantly reduced the
system heterogeneity are not suitable to clinical
reality, which underscores the importance of in-
cluding NCCA-mediated heterogeneity in the study
of human diseases.
One important realization is that the frequencies of
NCCAs can be used as a reliable index to measure the
genome instability of a given cell population or cell line.
Both internal instability and drug-induced instability
can be measured. The NCCAs/CCAs cycles have been
observed from all key transition stages of the cancer
evolution, from immortalization and transformation, to
metastasis and drug resistance [38, 55–59]. Increased
attention should be paid to more common and com-
plex diseases or illness conditions.
c. The function of genome heterogeneity: evolutionary
potential:
First, elevated levels of NCCAs were linked to
tumorigenicity, which again agree with the common
observation that multiple factors that contribute to
cancer can be linked to elevated NCCAs [59]. Then, the
punctuated phase of cancer evolution was linked to the
transcriptome dynamics [60]. Furthermore, outliers
were linked to evolutionary dominance under stress,
which ultimately demonstrated the importance of
NCCAs in cancer evolution [61]. In fact, when genome
chaos was induced by chemotherapy drugs, the massive
NCCAs became apparent as the key for cancer cells to
survive and quickly evolve to form much more stable
and simpler genomes [62]. Putting all of these
experiments/observations together, NCCAs represent
the evolutionary potential by creating new genome
systems with altered transcriptomes and phenotypes.
d. Mechanisms of maintaining NCCAs-mediated
heterogeneity and complexity:
In addition to stress-induced NCCA frequencies (of
both genetic and environmental origins), there are
internal mechanisms which maintain a certain degree
of heterogeneity. First, heterogeneity is not just a bad
thing for a biosystem caused by stress, but an import-
ant adaptation mechanism (even though too much is
certainly not good). We realized that a certain degree
of NCCAs is essential for normal cellular function
under stress. This idea explains the observation that
there are moderate or even high levels of NCCAs in
many healthy tissues, especially when adaptation is
needed (such as the aging process, wound healing,
tissue regeneration, and inflammation). Second, to
search for the mechanism of the internal basis for
generating and maintaining NCCAs in the first place,
we searched for a new type of inheritance at the som-
atic cell level, called fuzzy inheritance. It turns out
that genetic information is not as precise as we have
believed, but rather fuzzy. More specifically, for most
somatic cell traits, it is the range of genetic change
(such as the degree of NCCAs), rather than a specific
change (like a specific karyotype), that can be inher-
ited, especially for less stable cellular populations such
as some cancer cell populations. Such a genetic mech-
anism likely serves as the basis for the genetic hetero-
geneity of cancer. When coupled with somatic cell
evolution, precise prediction becomes much less so.
Interestingly, fuzzy inheritance combined with som-
atic cell evolution nicely explains the issue of missing
heritability [1, 54, 63–65]).
When faced with environmental dynamics, fixed
genetic information would have a great
disadvantage. The better strategy would be to inherit
an evolutionary potential which contains an array of
possible plans, rather than a fixed specific plan. The
separation of germline and somatic cells allow
somatic cells to display the highest level of change
by increasing the heterogeneity (for adaptation),
while the precise mechanism maintains the system
inheritance through the germline cells among
generations of individuals. Even though the
developmental process and the aging process can
bring about a great deal of somatic cellular-level
changes through the passing of fuzzy inheritance,
the species will not be impacted, as most of these
genome level changes will be washed away during
sexual reproduction. Somatic cell adaptation and
germline constraint forms a beautiful balance for
short-term adaptation and long-term species’ exist-
ence. It is clear that heterogeneity, functioning as a
new layer of complexity, plays an important role for
achieving such balance.
It is interesting to point out that under the high levels
of stress, the chaotic genome (including that of some
giant cells with hundreds of chromosomes) can push
fuzzy inheritance to the maximum [1, 12, 54, 65, 66].
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In such a situation, the generated cells can
display a highly altered genome, and even display
stem cell-like phenotypes, possibly achieving this
by drastically switching from mitotic to meiotic
machineries [66–70]. This drastic change is
caused by diverse survival mechanisms of the
genome. According to the genome theory, when
stress is too high to survive, re-organization of
the genome becomes the method of choice. In
this case, precise inheritance is less useful. In
contrast, highly fuzzy inheritance can produce a
large number of potential survivors, most of
which are distinctively different, and a tiny
portion of them will save the day. That is what
macro-cellular evolution is all about.
What action is needed for the cytogenetics community to
study and report NCCAs?
Over 60 years have passed since TC Hua developed the
hypotonic method to analyze the human karyotype [71].
Despite the fact that recurrent karyotype aberrations have
been used in medical genetics and played important role in
genetic diagnosis, cytogenetics has been thought of by
some as not as important as molecular genetics, as the
karyotype only represents the carrier of the genes rather
than gene itself. In fact, there are some premature sugges-
tions of using molecular methods such as array CGH and
DNA sequencing to replace karyotype analysis. Now, realiz-
ing that karyotype functions as the master that determines
the structure of the genetic network, and that NCCAs play
an important role in genome heterogeneity/complexity,
which is absolutely not replaceable by DNA-level profiling,
it is obvious that studying the mechanism of how the
karyotype and its heterogeneity works both in somatic cell
and organismal evolution should be much important than
illustrating the functions of individual genes. Interestingly,
the success of cytogenetics in the past has greatly enhanced
molecular genetics (chromosomal aberrations have helped
in the identification of many cancer genes, for example).
The domination of molecular genetics has unfortunately
reduced the significance of cytogenetics. Now, the success
and limitation of gene-centric research will finally put the
future cytogenetics back into the driver’s seat, as the
genome-defined system is much more important than the
sum of all parts of genes, and it is genome replacement-
mediated macro-cellular evolution (rather than gene
mutation-led micro-cellular evolution) that represents the
general mechanism for diseases like cancer. While exciting,
it is very challenging to develop a new technological plat-
form to advance the field based on the importance of the
karyotype and NCCAs. Followings are some suggestions:
a. Systematic characterization of different types of
NCCAs
Currently, when discussing NCCAs, most
researchers refer to non-recurrent chromosomal
translocations and aneuploidy. However, as we listed
in Table 1, there are many more types of chromo-
somal abnormalities belonging to this category,
including defective mitotic figures (DMF), sticky
chromosomes, chromosome fragmentations (C-
Frag), and highly diverse chaotic genomes (including
unstable giant nuclei, in which a series of transitions
occurs, cycling from polyploidy to altered diploid
chromosomes through multipolar and bipolar
mitoses). Our recent publications have summarized
these accumulated data over decades [12, 66]. The
list of types of NCCAs can grow further when more
investigators are interested in NCCAs. In addition to
chromosome-based abnormalities, there are many
strange-looking interphase nuclei that clearly are not
normal judged by their irregular morphology. Inter-
estingly, there are many novel types of chromosomal
aberrations following the induction of genome
chaos. Many of them seem not very stable; therefore,
it could be hard to observe in the more stable
systems. Further characterization is clearly needed.
b. Compare and integrate different types of NCCAs
Due to the large number and diverse types of NCCAs,
it is necessary to compare their contribution to
evolutionary potential as well as disease phenotypes.
For example, when measuring chromosomal instability
(CIN), we initially focused on structural NCCAs when
the system was highly unstable. The limitation of such
analyses is that the contribution of aneuploidy has been
ignored. Improved analyses need to include all types of
NCCAs, but how do we score them in the overall
contribution? Should we treat them equally or not?
Knowing that structural change might have more
profound impact than lower levels of aneuploidy [59], a
combinational score system is needed. Such
complication is far beyond aneuploidy. The
contribution of one single chromatid break is likely to
contribute less than a translocation, but is this true?
How many breaks should be equal to one translocation
when measuring their genetic contribution towards
CIN? How about the abnormality distribution within
cell the population? Is an individual cell with multiple
abnormalities more harmful than many cells displaying
only chromosomal aberration? And what about the
relationship between DMF and translocation, between
C-Frag and aneuploidy, and between simple transloca-
tion and complex translocations?
There are some further complications. The tolerance
of chromosomal abnormalities or CIN seems to
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differ among different tissue types. Liver tissue
displays a high level of tolerance to polyploidy and
aneuploidy, and embryogenic cells seem to be able
to tolerate more chaotic genomes. Should we modify
the score criteria when studying different types of
tissue? This issue also applies to different cancer
models, wherein a certain degree of CIN will make a
huge difference in terms of tumorigenesis. Now,
knowing that the two phases of cancer evolution are
involved, should we use a different calculation
matrix when scoring chromosomal aberration in
different phases of cancer evolution? Finally, it is
known that most of the specific NCCAs will be
eliminated (for those cells that can precisely pass
their inheritance by inheriting the same karyotype,
the CCAs will be emergent); as such, how do we
predict the survival rate of each type of NCCA? For
example, many cells displaying a lower degree of
aneuploidy will have greater chance to survive than
those with a highly re-shuffled genome with multiple
translocations. But when they survive, these cells
with complex genomes will have higher impact on
cancer evolution.
c. Establish the baseline of NCCAs for various tissues
One important technical issue is to differentiate real
noise (e.g. the cell culture and preparation artefacts
like over-spread metaphases) from NCCAs. In
addition to standardizing protocols, attention is
needed to reduce the technical variability. Interphase
FISH could be used to study the baseline of aneu-
ploidy, for example. Studies are also needed to quan-
tify the contribution from the cell culture process to
the baseline of various types of NCCAs. Similarly,
various tissues, as well as those of differently-aged of
individuals, should be used to establish the baseline.
A comparison between in vivo samples (using sensi-
tive DNA-cytometry methods) and in vitro culture
(using classical cytogenetic methods) is also needed.
d. Develop methods to access mitotic cells
One of the biggest limitations for karyotype analysis
is the requirement of mitotic figures. The need of
dividing cells excludes the usage of fixed
biomaterials such as fixed pathological slides. In
addition, in the case of many fresh tumor samples,
karyotype analysis often requires a short-term cell
culture (i.e., a few days, and especially if NCCAs will
be scored, as more mitotic figures are necessary),
which might introduce further chromosomal
changes. To solve this problem, methods are needed
to promote the presence of mitotic cells. Alterna-
tively, interphase FISH can be used with a panel of
probes to monitor aneuploidy and to infer structural
changes. To indirectly monitor genome chaos, it is
also possible to use a few whole chromosome paints
to study the organized chromosome using interphase
FISH.
e. Re-examine/interpret the NCCAs data
To illustrate NCCAs’ relevance in the clinic,
association studies are needed to link the types and
frequencies of NCCAs to some clinical features. We
have illustrated the linkage between overall genome
instability (reflected by the level of NCCAs) and the
formation of secondary cancer [72]. Similarly, we
have linked elevated NCCAs in circulating
lymphocytes to various cancer types and their
dynamics during treatments, as well as to some
other illness conditions such as Gulf War Illness
[[54, 66] unpublished data]. This supports previous
observations that elevated frequencies of NCCAs in
an individual’s blood can be linked to increased
cancer risk following exposure to irradiation [73]. In
fact, Dr. TC Hsu has hypothesized that genetic
instability in the human population contributes to
many cancer and other diseases, and that when
challenged, the cells of persons with mildly defective
repair systems may show a higher rate of
chromosome aberrations than those of persons with
stable repair systems [33]. With the realization that
increased CIN is not just due to defective repair
systems, but also the active response to stress as the
mechanism of cellular adaptation[1, 54, 65], many
more molecular mechanisms will be linked to CIN-
mediated diseases as the result of somatic cell evolu-
tion and its trade-off. NCCAs-defined CIN should
become the central subject for future research to il-
lustrate disease mechanisms, and more importantly,
NCCA/CCA profiling should be used to design diag-
nosis and treatment methods and for monitoring
clinical outcomes. One important example is the use
of the NCCAs to follow disease progression in can-
cer patients. Our experimental data has shown that
drug resistance is highly associated with elevated
NCCAs. In fact, even in the case of the successful
story of using imatinib to treat CML patients, when
the disease enters into the blast crisis stage, designated
by high frequencies of NCCAs, imatinib is no longer
useful [44]. Clearly, profiling patients’ NCCA/CCA
pattern is important for designing the treatment op-
tions. Another important issue is to link the NCCA/
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CCA contribution to the status of the individual’s
somatic mosaicism [74–76], as the degree of somatic
mosaicism is closely linked to the phenotypes [77].
f. Develop an NCCA database
For the majority of cytogenetic reports, the data of
NCCAs are largely missing, despite the fact that
many well-known structures such as ring chromo-
somes and chromosomal bridges are actually
NCCAs. It is important to report NCCAs and estab-
lish a database. Such a database will serve multiple
purposes. First, it will expand the list of types of
NCCAs. Second, it will record the frequencies of
different types of NCCAs and all types of NCCAs
for normal individuals, for specific disease types, and
for various tissue types. . Third, it will encourage the
re-examination of published reports to collect the
data, and initiate efforts to examine previous avail-
able samples. One interesting implication is to test
the possibility that some balanced translocations
might have no phenotype in parents, but could con-
tribute to instability in offspring (i.e., the offspring
could have the same balanced translocation as well
as increased NCCAs). Furthermore, some CCAs
(like balanced translocations) in conjunction with
additional NCCAs could display an improved or
worsened phenotype. Fourth, it will promote the in-
tegration of these data with other molecular data-
bases, such as integration with databases of DNA
sequence, copy number variation, small supernumer-
ary marker chromosomes, and various cytogenetic
databases [43, 78–80].
Conclusion
In closing, genome system instability is the ultimate link
between many diseases and their genetic and environ-
mental contributing factors. The genome serves as the
evolutionary platform that links gene/epigene interaction
and multiple levels of omics [1]. Using the types and fre-
quencies of NCCAs, and the dynamic relationship be-
tween NCCA and CCA, evolutionary potential can be
monitored either genetically or environmentally [81], as
all stress responses can be reflected by the level of sys-
tem instability. This evolutionary mechanism of diseases
can unify diverse molecular mechanisms, and reconcile
the difficulty of clinical prediction based only on the
genetic profile. Of equal importance, the significance of
NCCAs will emphasize the ultimate importance of
studying heterogeneity in biology, including heteromor-
phisms and euchromatic variants [54, 82–85]. Welcome
to the age of genome- (karyotype-) based cytogenetic/
genomic research!
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